X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (223) 223
esomeprazole (152) 152
male (143) 143
proton pump inhibitors (126) 126
female (122) 122
middle aged (106) 106
omeprazole (106) 106
index medicus (97) 97
gastroenterology & hepatology (89) 89
treatment outcome (87) 87
pharmacology & pharmacy (86) 86
adult (79) 79
2-pyridinylmethylsulfinylbenzimidazoles (77) 77
lansoprazole (77) 77
aged (76) 76
omeprazole - analogs & derivatives (66) 66
gastroesophageal reflux - drug therapy (65) 65
ticlopidine - analogs & derivatives (62) 62
anti-ulcer agents - therapeutic use (56) 56
esomeprazole - administration & dosage (53) 53
esomeprazole - therapeutic use (49) 49
omeprazole - therapeutic use (47) 47
rabeprazole (46) 46
double-blind method (45) 45
drug therapy, combination (45) 45
drug interactions (43) 43
pantoprazole (43) 43
anti-ulcer agents - administration & dosage (42) 42
esomeprazole - analogs & derivatives (40) 40
gastroesophageal-reflux disease (37) 37
aspirin (36) 36
clopidogrel (36) 36
proton pump inhibitors - therapeutic use (36) 36
prospective studies (33) 33
esomeprazole - adverse effects (31) 31
management (30) 30
dose-response relationship, drug (29) 29
proton pump inhibitor (29) 29
therapy (29) 29
benzimidazoles - therapeutic use (28) 28
cross-over studies (28) 28
drug administration schedule (28) 28
pharmacokinetics (28) 28
platelet aggregation inhibitors - adverse effects (27) 27
proton pump inhibitors - adverse effects (27) 27
risk (27) 27
erosive esophagitis (26) 26
hydrogen-ion concentration (26) 26
ticlopidine - adverse effects (26) 26
ticlopidine - therapeutic use (26) 26
risk factors (25) 25
gastroesophageal reflux disease (24) 24
omeprazole - administration & dosage (24) 24
omeprazole - pharmacology (24) 24
platelet aggregation inhibitors - therapeutic use (24) 24
proton-pump inhibitors (24) 24
adolescent (23) 23
anti-ulcer agents - pharmacology (23) 23
symptoms (23) 23
aged, 80 and over (22) 22
anti-ulcer agents - adverse effects (22) 22
esomeprazole - pharmacology (22) 22
double-blind (21) 21
efficacy (21) 21
enzyme inhibitors - therapeutic use (21) 21
follow-up studies (21) 21
medicine, general & internal (21) 21
omeprazole - pharmacokinetics (21) 21
administration, oral (20) 20
aspirin - adverse effects (20) 20
medicine & public health (20) 20
time factors (20) 20
helicobacter pylori (19) 19
nonsteroidal antiinflammatory drugs (19) 19
sulfoxides - therapeutic use (19) 19
animals (18) 18
disease (18) 18
drug therapy (18) 18
esophagitis (18) 18
helicobacter infections - drug therapy (18) 18
omeprazole - adverse effects (18) 18
anti-ulcer agents - pharmacokinetics (17) 17
proton pump inhibitors - administration & dosage (17) 17
benzimidazoles - administration & dosage (16) 16
care and treatment (16) 16
gastric acid - secretion (16) 16
gastroesophageal reflux (16) 16
internal medicine (16) 16
intragastric ph (16) 16
severity of illness index (16) 16
ticlopidine - administration & dosage (16) 16
esomeprazole - pharmacokinetics (15) 15
gastroesophageal reflux - diagnosis (15) 15
proton pump inhibitors - pharmacology (15) 15
safety (15) 15
aspirin - therapeutic use (14) 14
esophagitis, peptic - drug therapy (14) 14
gastroesophageal reflux - complications (14) 14
gastrointestinal hemorrhage - chemically induced (14) 14
heartburn (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (237) 237
German (3) 3
Spanish (2) 2
Chinese (1) 1
Danish (1) 1
Dutch (1) 1
French (1) 1
Japanese (1) 1
Korean (1) 1
Norwegian (1) 1
Polish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ugeskrift for laeger, 04/2013, Volume 175, Issue 14, p. 955
Information about "effect" was considered more important than "price" on analogue substitution by a group of patients using the original medicine, esomeprazol,... 
Anti-Ulcer Agents - economics | Drug Substitution - psychology | Drug Substitution - economics | Humans | Health Communication - standards | Drugs, Generic - economics | Patient Education as Topic - standards | Surveys and Questionnaires | Qualitative Research | Esomeprazole - economics
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently,... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | N | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2009, Volume 101, Issue 4, pp. 714 - 719
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 01/2017, Volume 906, pp. 325 - 350
Aspirin and P2Y(12) receptor antagonists are widely used across the spectrum of cardiovascular diseases. Upper gastrointestinal complications, including ulcer... 
Clopidogrel | Proton pump inhibitors | Aspirin | ADP receptor antagonists | Drug interactions | ACETYLSALICYLIC-ACID | MEDICINE, RESEARCH & EXPERIMENTAL | ACID 325 MG | PLATELET-FUNCTION | ACUTE CORONARY SYNDROMES | ESOMEPRAZOLE 40 MG | ENTERIC-COATED ASPIRIN | CONCOMITANT USE | COMBINING ASPIRIN | LOW-DOSE ASPIRIN | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | Cardiovascular Diseases - drug therapy | Humans | Aspirin - pharmacokinetics | Esomeprazole - blood | Cardiovascular Diseases - pathology | Cardiovascular Diseases - genetics | Drug Dosage Calculations | Drug Interactions | Gastrointestinal Hemorrhage - metabolism | Adenosine - therapeutic use | Hydrogen-Ion Concentration - drug effects | Ticlopidine - pharmacokinetics | Proton Pump Inhibitors - blood | Purinergic Antagonists - pharmacokinetics | Receptors, Purinergic P2Y12 - metabolism | Receptors, Purinergic P2Y12 - genetics | Gene Expression | Purinergic Antagonists - blood | Cardiovascular Diseases - metabolism | Drug Administration Schedule | Aspirin - blood | Esomeprazole - pharmacokinetics | Peptic Ulcer - metabolism | Peptic Ulcer - pathology | Ticlopidine - analogs & derivatives | Prasugrel Hydrochloride - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Proton Pump Inhibitors - pharmacokinetics | Adenosine - analogs & derivatives | Peptic Ulcer - chemically induced | Gastrointestinal Hemorrhage - pathology | Ticlopidine - blood
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 14, pp. 1304 - 1311
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2018, Volume 104, Issue 1, pp. 188 - 200
The accuracy of physiologically based pharmacokinetic (PBPK) model prediction in children, especially those younger than 2 years old, has not been... 
CLEARANCE | TISSUE DISTRIBUTION | IN-VIVO | VOLUME | ONTOGENY | PROTON PUMP INHIBITORS | PHARMACOLOGY & PHARMACY | PHARMACODYNAMICS | SIMULATION | DESLORATADINE | EXPOSURE | Humans | Anti-Asthmatic Agents - metabolism | Child, Preschool | Cytochrome P-450 Enzyme System - metabolism | Sufentanil - metabolism | Bronchodilator Agents - metabolism | Quinolines - pharmacokinetics | Theophylline - pharmacokinetics | Esomeprazole - metabolism | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Ondansetron - metabolism | Child | Cytochrome P-450 CYP2C9 - metabolism | Histamine H1 Antagonists, Non-Sedating - pharmacokinetics | Infant, Newborn | Itraconazole - metabolism | Serotonin Antagonists - pharmacokinetics | Tramadol - pharmacokinetics | Theophylline - metabolism | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Proton Pump Inhibitors - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Cytochrome P-450 CYP2D6 - metabolism | Serotonin Antagonists - metabolism | Analgesics, Opioid - metabolism | Diclofenac - metabolism | Lansoprazole - pharmacokinetics | Loratadine - pharmacokinetics | Sufentanil - pharmacokinetics | Infant | Anti-Asthmatic Agents - pharmacokinetics | Itraconazole - pharmacokinetics | Antifungal Agents - pharmacokinetics | Antifungal Agents - metabolism | Loratadine - metabolism | Cytochrome P-450 CYP2C8 - metabolism | Lansoprazole - metabolism | Acetates - metabolism | Esomeprazole - pharmacokinetics | Cytochrome P-450 CYP1A2 - metabolism | Ondansetron - pharmacokinetics | Tramadol - metabolism | Diclofenac - pharmacokinetics | Quinolines - metabolism | Pharmaceutical Preparations - metabolism | Proton Pump Inhibitors - pharmacokinetics | Bronchodilator Agents - pharmacokinetics | Analgesics, Opioid - pharmacokinetics | Cytochrome P-450 CYP2C19 - metabolism | Loratadine - analogs & derivatives | Histamine H1 Antagonists, Non-Sedating - metabolism | Pharmacokinetics | Acetates - pharmacokinetics
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 140, Issue 3, pp. 791 - 798.e2
Background & Aims We performed a prospective, randomized, controlled study to compare the combination of esomeprazole and clopidogrel vs clopidogrel alone in... 
Gastroenterology and Hepatology | Proton-Pump Inhibitor | Plavix | Drug Interactions | CYP2C19 | IMPACT | PREVENTION | OMEPRAZOLE | PROTON PUMP INHIBITORS | RISK | GASTROENTEROLOGY & HEPATOLOGY | ASPIRIN | Prospective Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Esomeprazole - adverse effects | Peptic Ulcer - prevention & control | Male | Secondary Prevention | Esomeprazole - therapeutic use | Time Factors | Platelet Function Tests | Ticlopidine - adverse effects | Aged, 80 and over | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Peptic Ulcer - complications | Atherosclerosis - drug therapy | Risk Assessment | Endoscopy, Gastrointestinal | Atherosclerosis - complications | Genotype | Treatment Outcome | Proton Pump Inhibitors - therapeutic use | Peptic Ulcer - pathology | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Atherosclerosis - blood | Phenotype | Cytochrome P-450 CYP2C19 | Taiwan | Aged | Peptic Ulcer - drug therapy | Care and treatment | Relapse | Pharmacy | Drug interactions | Cytochrome P-450 | Atherosclerosis | Peptic ulcer | Proton pump inhibitors | Comparative analysis | Diseases
Journal Article